Uses of Rythmosin 150: - Arrhythmia Supraventricular and ventricular arrhythmias, Atrial Fibrillation/Flutter Uncontrolled heart failure, marked hypotension, severe bradycardia and heart block, conduction abnormalities, cardiogenic shock, myasthenia gravis.

Membrane stabilizing agent (Sodium channel blockers)

Propafenone works by slowing the influx of sodium ions into the cardiac muscle cells, causing a decrease in excitability of the cells. Propafenone is more selective for cells with a high rate, but also blocks normal cells more than class Ia or Ib. Propafenone differs from the prototypical class Ic antiarrhythmic in that it has additional activity as a beta-adrenergic blocker which can cause bradycardia and bronchospasm.

How to use Propafenone Hydrochloride: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Propafenone Hydrochloride is to be taken with food. Administration: Should be taken with food. Take after meals. Swallow whole, do not chew/crush. Adult Dose: Oral Supraventricular and ventricular arrhythmias, Atrial Fibrillation/Flutter Adult: For immediate-release tablet: Usual initial doses: 150 mg tid, may increase at intervals of 3-4 days up to 300 mg tid. Dose reduction is recommended in patients weighing <70 kg. Elderly: Dose reduction is recommended. Hepatic impairment: Dose reduction is recommended. Child Dose: Safety and efficacy not established

Effect may be potentiated by local anesth, beta-blockers, TCA. May increase plasma level of propranolol, metoprolol, desipramine, cyclosporin, digoxin, theophylline. Plasma conc may rise when taken simultaneously w/ cimetidine or quinidine. May enhance effect of anticoagulant. Simultaneous administration w/ phenobarb or rifamycin may decrease propafenone plasma conc, possibly in sub-therapeutic levels.

Uncontrolled heart failure, marked hypotension, severe bradycardia and heart block, conduction abnormalities, cardiogenic shock, myasthenia gravis.

Common - Abdominal pain - Anxiety - Blurred vision - Breathlessness - Chest pain - Constipation - Dizziness - Dryness in mouth - Fatigue - Fever - Headache - Increased liver enzymes - Palpitations - Sleep disorder - Taste change - Visual impairment - Vomiting - Weakness >10% Unusual taste (7-23%),Dizziness/lightheadedness (7-15%),N/V (3-11%) 1-10% Constipation (4-8%),Headache (2-6%),Intraventricular conduction delay (4%),Fatigue (6%),Blurred vision (3%),Weakness (3%),Dyspnea (2%),Wild complex tachycardia (2%),Bradycardia (2%),Palpitations (2%),Tremor (2%),Anorexia (2%),Diarrhea (2%),Ataxia (2%),1°AV block (2-5%),Angina (5%),Palpitations (3%),CHF (2-3% ),Chest pain (2%),Bradyarrhythmia (2%),AF (1%),Bundle branch block (1%),2nd degree AV block (1%),Hypotension (1%),Sinus arrest (1%) Frequency Not Defined Lethargy,Rash,Dyspepsia,Dry mouth,Agranulocytosis,Hepatotoxicity (rare),Systemic lupus erythematosus (rare),Bronchospasm (rare) Potentially Fatal: SA/AV or intraventricular blocks. Severe hypotension, especially in elderly.

Pregnancy: Propafenone has been assigned to pregnancy category C by the FDA. There are no controlled data in human pregnancy. Limited data indicate that propafenone has been administered during the third trimester of pregnancy without adverse maternal or fetal effects. Propafenone should be given during pregnancy only when benefit outweighs risk.Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from propafenone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Precaution: Severe pulmonary obstructive diseases, CHF, cardiac pacemaker, impaired renal/hepatic function, pregnancy, lactation, elderly. Correct electrolyte disturbances before starting treatment. May worsen heart failure in patients with preexisting organic heart disease. May worsen or cause new severe ventricular arrhythmias e.g. ventricular tachycardia or fibrillation. May aggravate electrically induced ventricular tachycardia in some patients. Lactation: Crosses into breast milk; discontinue drug or do not nurse

Store at 25° C. Store in a cool and dry place, protected from light. Keep out of children’s reach.

Membrane stabilizing agent (Sodium channel blockers)

Propafenone is a class 1C antiarrhythmic drug with local anaesthetic effects, and a direct stabilising action on myocardial membranes. The electrophysiological effect manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity.

Pregnancy: Propafenone has been assigned to pregnancy category C by the FDA. There are no controlled data in human pregnancy. Limited data indicate that propafenone has been administered during the third trimester of pregnancy without adverse maternal or fetal effects. Propafenone should be given during pregnancy only when benefit outweighs risk.Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from propafenone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.